{"id":296419,"date":"2022-09-19T00:00:00","date_gmt":"2022-09-19T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0004-2022-biopharma-epilepsy-current-treatment-current-treatment-physician-insights-epilepsy\/"},"modified":"2026-03-31T10:38:31","modified_gmt":"2026-03-31T10:38:31","slug":"cutrcg0004-2022-biopharma-epilepsy-current-treatment-current-treatment-physician-insights-epilepsy-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0004-2022-biopharma-epilepsy-current-treatment-current-treatment-physician-insights-epilepsy-us\/","title":{"rendered":"Epilepsy &#8211; Current Treatment &#8211; Current Treatment: Physician Insights &#8211; Epilepsy (US)"},"content":{"rendered":"<p>For neurologists, established molecules like leveteriacetam, lamotrigine, and carbamazepine remain the first choice of treatment for epilepsy; however, the new entrants in the market are evoloving the dynamics of this stable market and offering\u00a0safe and efficacious choices, especially for orphan subpopulations of the disease like\u00a0<abbr data-abbreviation-entity=\"5075\" title=\"Lennox-Gastaut syndrome\">LGS<\/abbr> and <abbr data-abbreviation-entity=\"7369\" title=\"Dravet syndrome\">DS<\/abbr>. This report will explore neurologists\u2019 perceptions of established and newly launched <u><abbr data-abbreviation-entity=\"4723\" title=\"antiepileptic drug\">AED<\/abbr>s,<\/u>\u00a0their prescribing habits in today\u2019s market, and anticipated changes in brand usage as more <u><abbr title=\"antiepileptic drug\">AED<\/abbr>s\u00a0<\/u>expand\u2014and further complicate\u2014prescriber choice.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How are different <u>epilepsy<\/u>\u00a0subpopulations (i.e., <abbr data-abbreviation-entity=\"8349\" title=\"partial-onset seizures\">POS<\/abbr>, <abbr data-abbreviation-entity=\"8721\" title=\"generalized-onset seizures\">GOS<\/abbr>, <abbr data-abbreviation-entity=\"5075\" title=\"Lennox-Gastaut syndrome\">LGS<\/abbr>, and <abbr data-abbreviation-entity=\"7369\" title=\"Dravet syndrome\">DS<\/abbr>) treated today?<\/li>\n<li>How do product shares differ across lines of therapy? Are high-efficacy therapies factoring more into early-line treatment decisions?<\/li>\n<li>How has neurologists\u2019 prescribing changed in the past year, and why? What further changes do they expect within the next year?<\/li>\n<li>What are neurologists\u2019 opinions of the newest entrants in the epilepsy\u00a0market, and how are they incorporating these <u><abbr data-abbreviation-entity=\"4723\" title=\"antiepileptic drug\">AED<\/abbr>s<\/u>\u00a0in the treatment paradigm?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p><em>Current Treatment: Physician Insights <\/em>provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.<\/p>\n<p><strong>Markets covered:<\/strong><strong>\u00a0<\/strong>US<\/p>\n<p><strong>Primary research:<\/strong><strong> <\/strong> Survey of 102 neurologists in the United States<\/p>\n<p><strong>Key drugs covered: <\/strong>Keppra, Lamictal, Depakene, Vimpat, Fycompa, Briviact, Xcopri, Epidiolex, Fintepla<\/p>\n<p><strong>Key companies: <\/strong>UCB, Sunovion, Biocodex, SK Biopharmaceuticals, GW Pharmaceuticals, Zogenix, Eisai\u00a0<\/p>\n<p><strong>Key insights provided:<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Factors influencing disease management and treatment decisions.<\/li>\n<li>Drivers and constraints of treatment selection.<\/li>\n<li>Physician-reported treatment practices and brand-level patient shares.<\/li>\n<li>Rationale for changes in treatment approach.<\/li>\n<li>Physician insight on persistency and compliance.<\/li>\n<li>Physician-reported recent \/ anticipated changes in brand usage or treatment approach.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-296419","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-epilepsy","biopharma-therapy-areas-neurology","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296419","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296419\/revisions"}],"predecessor-version":[{"id":296639,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296419\/revisions\/296639"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296419"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}